Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.65 |
| ▸ | NSD2 | O96028 | 3/20 | 0.61 |
| ▸ | WHR1 | P49842 | 5/20 | 0.59 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.58 |
| ▸ | CCR4 | P51679 | 1/20 | 0.55 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31016448 | 0.91 | EHMT2 (0.77) | EHMT2NSD2WHR1EHMT1CCR4 | |
| SCHEMBL22144764 | 0.91 | EHMT2 (0.77) | EHMT2NSD2WHR1EHMT1CCR4 | |
| SCHEMBL31016443 | 0.91 | EHMT2 (0.77) | EHMT2NSD2WHR1EHMT1CCR4 | |
| SCHEMBL25364389 | 0.88 | NSD2 (0.62) | EHMT2NSD2WHR1EHMT1CCR4 | |
| SCHEMBL25360878 | 0.88 | EHMT2 (0.83) | EHMT2NSD2EHMT1 | |
| SCHEMBL25361364 | 0.86 | EHMT2 (0.66) | EHMT2NSD2EHMT1CCR4 | |
| SCHEMBL25361879 | 0.86 | WHR1 (0.71) | EHMT2NSD2WHR1EHMT1CCR4 | |
| SCHEMBL25360325 | 0.85 | EHMT2 (0.65) | EHMT2NSD2EHMT1 | |
| SCHEMBL25360864 | 0.85 | EHMT2 (0.83) | EHMT2WHR1EHMT1CCR4 | |
| SCHEMBL25361910 | 0.85 | EHMT2 (0.63) | EHMT2NSD2EHMT1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630531-B2 | Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | OMIC SMAP INC. (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4230624-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | The Asan Foundation (KR) | 2023-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630531-B2 | Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | EHMT2, EHMT1, HNMT | EHMT2 1/4885NSD2 61/4885WHR1 996/4885 |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | EHMT2, EHMT1, HNMT | EHMT2 1/4885NSD2 39/4885WHR1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.